BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 32161005)

  • 1. Risk factors for subretinal fibrosis after anti-VEGF treatment of myopic choroidal neovascularisation.
    Xiao H; Zhao X; Li S; Sun L; Xin W; Wang Z; Zhang A; Zhang J; Ding X
    Br J Ophthalmol; 2021 Jan; 105(1):103-108. PubMed ID: 32161005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of intravitreal injection of aflibercept or ranibizumab on chorioretinal atrophy in myopic choroidal neovascularization.
    Sayanagi K; Uematsu S; Hara C; Wakabayashi T; Fukushima Y; Sato S; Ikuno Y; Nishida K
    Graefes Arch Clin Exp Ophthalmol; 2019 Apr; 257(4):749-757. PubMed ID: 30643966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SUBRETINAL FIBROSIS AFTER ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN EYES WITH MYOPIC CHOROIDAL NEOVASCULARIZATION.
    Ahn SJ; Park KH; Woo SJ
    Retina; 2016 Nov; 36(11):2140-2149. PubMed ID: 27124880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subfoveal Choroidal Thickness Changes Following Anti-Vascular Endothelial Growth Factor Therapy in Myopic Choroidal Neovascularization.
    Ahn SJ; Park KH; Woo SJ
    Invest Ophthalmol Vis Sci; 2015 Sep; 56(10):5794-800. PubMed ID: 26325418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. APPLICATION OF OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY TO ASSESS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN MYOPIC CHOROIDAL NEOVASCULARIZATION.
    Cheng Y; Li Y; Huang X; Qu Y
    Retina; 2019 Apr; 39(4):712-718. PubMed ID: 29256987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HOW VITREOMACULAR INTERFACE MODIFIES THE EFFICACY OF ANTI-VEGF THERAPY FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
    Iacono P; Battaglia Parodi M; Iuliano L; Bandello F
    Retina; 2018 Jan; 38(1):84-90. PubMed ID: 28098725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluorescein Leakage and Optical Coherence Tomography Features of Choroidal Neovascularization Secondary to Pathologic Myopia.
    Battaglia Parodi M; Iacono P; Romano F; Bandello F
    Invest Ophthalmol Vis Sci; 2018 Jun; 59(7):3175-3180. PubMed ID: 30025121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of treatment response to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy for choroidal neovascularisation secondary to chronic central serous chorioretinopathy.
    Romdhane K; Zola M; Matet A; Daruich A; Elalouf M; Behar-Cohen F; Mantel I
    Br J Ophthalmol; 2020 Jul; 104(7):910-916. PubMed ID: 31615761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FACTORS INFLUENCING VISUAL ACUITY IN PATIENTS RECEIVING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
    Iacono P; Battaglia Parodi M; Selvi F; Parravano MC; Chiaravalloti A; Varano M; Bandello F
    Retina; 2017 Oct; 37(10):1931-1941. PubMed ID: 28033235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Morphological parameters of myopic choroidal neovascularization as predictive factors of anti-VEGF treatment response.
    Castellino N; Battaglia Parodi M; Russo A; Toro MD; Fallico M; Bonfiglio V; Maugeri AD; Avitabile T; Longo A
    Sci Rep; 2022 Jun; 12(1):10435. PubMed ID: 35729226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. OLIMPIC: a 12-month study on the criteria driving retreatment with ranibizumab in patients with visual impairment due to myopic choroidal neovascularization.
    Ricci F; Staurenghi G; Varano M; Eandi C; Sinibaldi TL; Colombo L; Bartezaghi M; Bassanini S
    Graefes Arch Clin Exp Ophthalmol; 2019 Apr; 257(4):759-768. PubMed ID: 30680452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcomes of myopic choroidal neovascularisation treated with combined ranibizumab and dexamethasone characterised by multi-modal imaging.
    Tan AC; Teo K; Guan OS; Koh A
    Graefes Arch Clin Exp Ophthalmol; 2016 Oct; 254(10):1881-1888. PubMed ID: 26968717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors of eyes with naïve subfoveal myopic choroidal neovascularization after intravitreal bevacizumab.
    Yang HS; Kim JG; Kim JT; Joe SG
    Am J Ophthalmol; 2013 Dec; 156(6):1201-1210.e2. PubMed ID: 24075429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of intravitreal ranibizumab injections on aqueous humour concentrations of vascular endothelial growth factor and pigment epithelium-derived factor in patients with myopic choroidal neovascularisation.
    Costagliola C; Semeraro F; dell'Omo R; Romano MR; Russo A; Aceto F; Mastropasqua R; Porcellini A
    Br J Ophthalmol; 2015 Jul; 99(7):1004-8. PubMed ID: 25770144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison between anti-vascular endothelial growth factor therapy and photodynamic therapy for myopic choroidal neovascularization.
    Matsuo M; Honda S; Matsumiya W; Kusuhara S; Tsukahara Y; Negi A
    Eur J Ophthalmol; 2012; 22(2):210-5. PubMed ID: 21534251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results.
    Ikuno Y; Sayanagi K; Soga K; Sawa M; Tsujikawa M; Gomi F; Tano Y
    Am J Ophthalmol; 2009 Jan; 147(1):94-100.e1. PubMed ID: 18774550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural and optical coherence tomography angiography in myopic choroidal neovascularization: Agreement with conventional fluorescein angiography.
    Iacono P; Giorno P; Varano M; Parravano M
    Eur J Ophthalmol; 2021 Jan; 31(1):149-157. PubMed ID: 31619075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term variable outcome of myopic choroidal neovascularization treated with ranibizumab.
    Cohen SY; Nghiem-Buffet S; Grenet T; Dubois L; Ayrault S; Fajnkuchen F; Delahaye-Mazza C; Quentel G; Tadayoni R
    Jpn J Ophthalmol; 2015 Jan; 59(1):36-42. PubMed ID: 25416566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VISUAL ACUITY OUTCOMES OF RANIBIZUMAB TREATMENT IN PATHOLOGIC MYOPIC EYES WITH MACULAR RETINOSCHISIS AND CHOROIDAL NEOVASCULARIZATION.
    Ceklic L; Munk MR; Wolf-Schnurrbusch U; Gekkieva M; Wolf S
    Retina; 2017 Apr; 37(4):687-693. PubMed ID: 27533774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.
    Sharma S; Toth CA; Daniel E; Grunwald JE; Maguire MG; Ying GS; Huang J; Martin DF; Jaffe GJ;
    Ophthalmology; 2016 Apr; 123(4):865-75. PubMed ID: 26783095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.